Rejuvenate Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Rejuvenate Bio to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Rejuvenate Bio, a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

“We’re excited to share data at ASGCT 2024 on our RJB-0402 gene therapy which targets key disease-mediating pathways in arrhythmogenic cardiomyopathy (ACM),” said Noah Davidsohn, PhD., Chief Scientific Officer at Rejuvenate Bio. “ACM is an inherited disease caused by mutations in one of several genes encoding desmosomal proteins, and there is an urgent need for better treatment options. If our approach proves effective to treat ACM, it would have a dramatic impact on the profound burden this disease has on patients and their families.”

Title: AAV FGF21 Gene Therapy as a Variant Agnostic Treatment for Arrhythmogenic Cardiomyopathy
Session Type: In-Person Oral Presentation
Session Title: Next Generation Gene & Cell Therapies for Heart, Lung, and Kidney Diseases
Abstract Number: 79
Location: Room 314-317
Session Date/Time: Wednesday May 8, 2024 1:30 PM - 3:15 PM

Abstracts will be released to the public on April 22, 2024, at 4:30 p.m. ET at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 8, 2024. A copy of the presentation will be available at www.rejuvenatebio.com once the presentation concludes.

About Rejuvenate Bio

Rejuvenate Bio is a biotechnology company dedicated to developing novel gene therapies for chronic age-related diseases. Rejuvenate Bio has built a gene therapy pipeline with huge potential in chronic disease by utilizing clinically validated gene targets and a delivery approach that ensures well tolerated, durable expression. Founded on scientific research developed at the Wyss Institute at Harvard Medical School, Rejuvenate Bio has developed groundbreaking therapies to treat chronic age-related disease in both humans and animals. The company is headquartered in San Diego, CA. For more information, visit www.rejuvenatebio.com.

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240422314060/en/